Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on May 30, 2018. The registrant is a California corporation focused on the DetermaVu product candidate. The report details executive compensation adjustments and a change in corporate governance procedure regarding authorized stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation grants and corporate actions.
Material Changes and Events
- Executive Stock Option Grants: On May 23, 2018, the Compensation Committee granted stock options to executives and employees with an exercise price of $2.35 per share (the closing price on the prior trading day).
- William Annett (CEO): 180,000 shares. Vesting is tied to Clinical Validation (25%) and Medicare Local Coverage Determination (LCD Approval) for the remaining shares.
- Mitchell Levine: 50,000 shares (time-based vesting: 25% at one year, then monthly) and 125,000 shares (performance-based vesting tied to Clinical Validation, LCD Filing, and LCD Approval).
- Lyndal Hesterberg and Kristine Mechem: 150,000 and 125,000 shares respectively, vesting based on Clinical Validation, LCD Filing, and LCD Approval.
- Non-Executive Employees/Consultants: Up to 375,200 shares, vesting based on the same three performance milestones.
- Cost Reduction Measures: The company is considering cost-reduction efforts, including potential option awards in exchange for employee sabbaticals or salary reductions.
- Stock Authorization Change: A preliminary information statement filed on May 7, 2018, regarding a potential increase in authorized common stock via written consent was abandoned. The company will not file a definitive information statement for this action via written consent; it may be included as an agenda item for the 2018 annual shareholder meeting.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to risks disclosed in Forms 10-K and 10-Q. The company explicitly disclaims any obligation to update these statements. The vesting of the majority of the new option grants is contingent upon the successful completion of clinical utility studies and the receipt of Medicare coverage determinations for the DetermaVu product candidate.
Investor Verification Checklist
- Verify the total number of shares authorized and outstanding to assess the dilution impact of the 830,200 new options granted.
- Confirm the current status of the DetermaVu clinical utility study and Medicare LCD filing, as these are critical vesting triggers for executive compensation.
- Review the upcoming 2018 annual meeting agenda to determine if the increase in authorized stock will be proposed.
- Monitor subsequent filings for details on the implementation of cost-reduction measures, such as salary reductions or sabbaticals.